GRFS vs. MDCX

Last updated Aug 1, 2026

GRFS (Grifols, S.A.) and MDCX (Medicus Pharma Ltd) are both stocks. Both are in the Healthcare sector — GRFS in Drug Manufacturers - General, MDCX in Biotechnology. Over the past year, GRFS returned -24.76% vs -89.29% for MDCX. Their 0.06 correlation means their historical movements had little consistent relationship.

Performance

GRFS vs. MDCX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Grifols, S.A. (GRFS) and Medicus Pharma Ltd (MDCX). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, GRFS achieves a -14.69% return, which is significantly higher than MDCX's -82.01% return.

GRFS

• 1D: -4.02%
• 1M: 9.92%
• 6M: -13.77%
• YTD: -14.69%
• 1Y: -24.76%
• 3Y*: -7.54%
• 5Y*: -11.82%
• 10Y*: -6.06%
• ALL TIME*: 3.18%

MDCX

• 1D: 4.80%
• 1M: -33.89%
• 6M: -76.87%
• YTD: -82.01%
• 1Y: -89.29%
• 3Y*: —
• 5Y*: —
• 10Y*: —
• ALL TIME*: -75.77%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison

Position	Avg. Volume Value (2W)	Avg. Volume Value (1M)	Avg. Volume Value (3M)
GRFS Grifols, S.A.	$7.99M	$6.47M	$5.41M
MDCX Medicus Pharma Ltd	$505.47K	$499.43K	$773.71K

GRFS vs. MDCX - Yearly Performance Comparison

	2026 (YTD)	2025	2024
GRFS Grifols, S.A.	-14.69%	27.79%	-18.15%
MDCX Medicus Pharma Ltd	-82.01%	-37.04%	-21.61%

Correlation

The correlation between GRFS and MDCX is 0.04, meaning there was essentially no consistent relationship between their historical price movements. Each responded to its own set of market drivers.

	Correlation
Correlation (1Y) Focuses on recent behavior, but can change the most.	0.04
Correlation (All Time) Calculated using the full available price history since Nov 14, 2024	0.06

Fundamentals

Market Cap GRFS : $6.66B MDCX : $6.07M
EPS GRFS : €0.89 MDCX : -$1.92
Total Revenue (TTM) GRFS : €7.43B MDCX : $0.00
Gross Profit (TTM) GRFS : €2.77B MDCX : $0.00
EBITDA (TTM) GRFS : €1.75B MDCX : -$36.18M

Return for Risk

GRFS vs. MDCX — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

GRFS

GRFS Risk / Return Rank: 14
GRFS Sharpe Ratio Rank: 10
GRFS Sortino Ratio Rank: 13
GRFS Omega Ratio Rank: 14
GRFS Calmar Ratio Rank: 17
GRFS Martin Ratio Rank: 15

MDCX

MDCX Risk / Return Rank: 8
MDCX Sharpe Ratio Rank: 13
MDCX Sortino Ratio Rank: 8
MDCX Omega Ratio Rank: 8
MDCX Calmar Ratio Rank: 3
MDCX Martin Ratio Rank: 7

The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

GRFS vs. MDCX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Grifols, S.A. (GRFS) and Medicus Pharma Ltd (MDCX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	GRFS	MDCX	Difference
Sharpe ratio: Return per unit of total volatility	-0.77	-0.70	-0.07
Sortino ratio: Return per unit of downside risk	-0.96	-1.37	+0.40
Omega ratio: Gain probability vs. loss probability	0.89	0.83	+0.06
Calmar ratio: Return relative to maximum drawdown	-0.71	-0.98	+0.27
Martin ratio: Return relative to average drawdown	-1.20	-1.45	+0.25

GRFS vs. MDCX - Sharpe Ratio Comparison

The current GRFS Sharpe Ratio is -0.77, which is comparable to the MDCX Sharpe Ratio of -0.70. The chart below compares the historical Sharpe Ratios of GRFS and MDCX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

GRFS vs. MDCX - Drawdown Comparison

The maximum GRFS drawdown since its inception was -78.01%, smaller than the maximum MDCX drawdown of -96.62%. Use the drawdown chart below to compare losses from any high point for GRFS and MDCX.

Drawdown Indicators

	GRFS	MDCX	Difference
Max Drawdown Largest peak-to-trough decline	-78.01%	-96.62%	+18.61%
Max Drawdown (1Y) Largest decline over 1 year	-34.08%	-90.62%	+56.54%
Max Drawdown (3Y) Largest decline over 3 years	-52.68%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-65.42%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-78.01%	—	—
Current Drawdown Current decline from peak	-67.39%	-96.46%	+29.07%
Average Drawdown Average peak-to-trough decline	-32.11%	-60.11%	+28.00%
Ulcer Index Depth and duration of drawdowns from previous peaks	20.24%	61.30%	-41.06%

Volatility

GRFS vs. MDCX - Volatility Comparison

The current volatility for Grifols, S.A. (GRFS) is 10.35%, while Medicus Pharma Ltd (MDCX) has a volatility of 33.61%. This indicates that GRFS experiences smaller price fluctuations and is considered to be less risky than MDCX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	GRFS	MDCX	Difference
Volatility (1M) Calculated over the trailing 1-month period	10.35%	33.61%	-23.26%
Volatility (6M) Calculated over the trailing 6-month period	24.92%	123.42%	-98.50%
Volatility (1Y) Calculated over the trailing 1-year period	31.49%	126.72%	-95.23%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	48.92%	130.72%	-81.80%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	40.35%	130.72%	-90.37%

Dividends

GRFS vs. MDCX - Dividend Comparison

GRFS's dividend yield for the trailing twelve months is around 3.43%, while MDCX has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
GRFS Grifols, S.A.	3.43%	1.88%	0.00%	0.00%	0.00%	3.20%	0.83%	1.55%	2.32%	1.24%	1.67%	2.01%
MDCX Medicus Pharma Ltd	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials

Frequently Asked Questions

Can I hold both GRFS and MDCX in my portfolio?

GRFS and MDCX have a correlation of 0.04, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, GRFS or MDCX?

MDCX has higher volatility (33.61%) compared to GRFS (10.35%). In terms of maximum drawdown, GRFS dropped -78.01% vs MDCX's -96.62%.

Which has better risk-adjusted returns?

MDCX currently has the higher Sharpe Ratio (-0.70 vs -0.77), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.